226 -5 (79) 2025 - Djabbarova N.M. - EFFECT OF DAPAGLIFLOSIN IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE WITH INSULIN RESISTANCE

EFFECT OF DAPAGLIFLOSIN IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE WITH INSULIN RESISTANCE

Djabbarova N.M. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Recent evidence suggests that sodium glucose cotransporter-2 (SGLT2) inhibitors inhibit the development of non-alcoholic steatohepatitis in humans, as well as improve liver steatosis in obese patients with type 2 diabetes [1]. Although there are currently no specific approved drugs specifically for the treatment of NAFLD, recent multiple studies have focused on the efficacy of new antidiabetic drugs, as type 2 diabetes mellitus is closely associated with NAFLD and its more severe histological forms. We used 10 mg of dapagliflozin for 3 months in 30 patients with non-alcoholic fatty liver disease aged 20-65 еars. Our study showed the potential efficacy of an SGLT-2 inhibitor in NAFLD in patients without diabetes mellitus. The results showed a significant improvement in biochemical parameters, insulin sensitivity, lipid profile, body component composition, and weight loss during dapagliflozin therapy for NAFLD.

Keywords: Non-alcoholic fatty liver disease, steatosis, Dapagliflozin, SGLT2 inhibitors

First page

1123

Last page

1127

For citation:Djabbarova N.M. - EFFECT OF DAPAGLIFLOSIN IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE WITH INSULIN RESISTANCE//New Day in Medicine 5(79)2025 1123-1127 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

1. Omari, M. B., Naseri, S., Hassan, A. J. (2024). Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects. Diabetes, metabolic syndrome and obesity : targets and therapy, 17, 1131–1141. https://doi.org/10.2147/DMSO.S448670
2. Cotter, T. G., & Rinella, M. (2020). Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology, 158(7), 1851–1864. https://doi.org/10.1053/j.gastro.2020.01.052
3. Mamasolievna, J. N. Antidiabetic drugs in the treatment of non-alcoholic fatty liver disease: A literature review. Gospodarka i Innowacje., 2024, 48, 6-13.
4. Agababyan R. Irina, Djabbarova M. Nafisa. Current issues in modern treatment of nonalcoholic fatty liver disease // Journal of Biomedicine and Practice. 2024, vol. 9, issue 2, pp.44-54
5. Агабабян И.Р., Хохлачева Д.С., Ким Г.С., Хохлачева Н.А. Изучение компонентного состава организма на ранней стадии неалкогольной жировой болезни печени. Рецепт, 2024, том 27, № 1, 120-126. https://doi.org/10.34883/PI.2024.27.1.007
6. Targher, G., Tilg, H., & Byrne, C. D. (2021). Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. The lancet. Gastroenterology hepatology, 6(7), 578–588. https://doi.org/10.1016/S2468-1253(21)00020-0
7. Ribeiro Dos Santos, L., & Baer Filho, R. (2020). Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients. Metabolism open, 5, 100028. https://doi.org/10.1016/j.metop.2020.100028
8. Tobita, H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017). Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. Current therapeutic research, clinical and experimental, 87, 13–19. https://doi.org/10.1016/j.curtheres.2017.07.002
9. Gameil, M.A., Abdelgawad, M., Bahgat, M.H., Elsebaie, A.H., & Marzouk, R.E. (2020). Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus. The Egyptian Journal of Internal Medicine, 32.
10. Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B. (2018). Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia, 61(10), 2155–2163. https://doi.org/10.1007/s00125-018-4702-3
11. Eriksson, J. W., Lundkvist, P., Jansson, P. A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G. B., Risérus, U., Lind, L., & Oscarsson, J. (2018). Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia, 61(9), 1923–1934. https://doi.org/10.1007/s00125-018-4675-2

    file

    download